Outcome of the Board Meeting and Submission of the Audited Standalone Financial Results for the Half year and year ended March 31, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shelter Pharma Ltd reported audited standalone financial results for FY26 ended March 31, 2026. Revenue from operations grew 44.4% to Rs. 7,313.36 Lakhs from Rs. 5,066.02 Lakhs in FY25. Profit after tax increased 24.7% to Rs. 902.72 Lakhs from Rs. 723.74 Lakhs. Basic EPS improved to Rs. 6.57 from Rs. 5.16. However, the company reported negative operating cash flow of Rs. 1,248.01 Lakhs due to significant increases in inventories (up Rs. 1,154.37 Lakhs), trade receivables (up Rs. 233.20 Lakhs), and short-term loans and advances (up Rs. 1,067.81 Lakhs). The statutory auditor issued an unmodified (clean) opinion on the financial results. The company also raised Rs. 2,531.20 Lakhs through preferential issue of convertible warrants that were converted to equity shares. A new internal auditor (CA Ismail Ibrahimbhai Lakhani) was appointed for FY27.
Strong revenue growth demonstrates business expansion, but the negative operating cash flow despite higher profits signals working capital stress that investors should monitor closely. The clean audit opinion is positive for investor confidence.